Yongzhi Lu

Yongzhi Lu

Auto-generated profile, based on publicly available information

Yongzhi Lu

Guangzhou National Laboratory, Guangzhou, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYongzhi Lu
Yongzhi Lu
QYQi Yang
Qi Yang
RTRan Ting
Ran Ting
GZGuihua Zhang
Guihua Zhang
WLWenqi Li
Wenqi Li
JSJinsai Shang
Jinsai Shang
The RNA-dependent RNA polymerase (RdRp), 3C-like protease (3CLpro), and papain-like protease (PLpro) are pivotal components in the viral life cycle of SARS-CoV-2, presenting as promising therapeutic targets. Currently, all FDA-approved antiviral drugs against SARS-CoV-2 are RdRp or 3CLpro inhibitors. However, the mutations causing drug resistance have been observed in RdRp and 3CLpro from SARS-CoV-2, which makes it necessary to develop antivirals with novel mechanisms. Through the application of a structure-based drug design (SBDD) approach, we discover a series of novel potent non-covalent PLpro inhibitors with remarkable in vitro potency and in vivo PK properties. The co-crystal structures of PLpro with lead compounds reveal that the residues D164 and Q269 around the S2 site are critical for improving the inhibitor’s potency. The lead compound GZNL-P36 not only inhibits SARS-CoV-2 and its variants at the cellular level with EC50 ranging from 58.2 nM to 306.2 nM, but also inhibits HCoV-NL63 and HCoV-229E with EC50 of 81.6 nM and 2.66 μM, respectively. Oral administration of the GZNL-P36 results in significantly improved survival and notable reductions in lung viral loads and lesions in SARS-CoV-2 infection mouse model, consistent with RNA-seq data analysis. Our results indicate that PLpro inhibitors represent a promising SARS-CoV-2 therapy.

4 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
YLYongzhi Lu
Yongzhi Lu
QYQi Yang
Qi Yang
TRTing Ran
Ting Ran
GZGuihua Zhang
Guihua Zhang
WLWenqi Li
Wenqi Li
JSJinsai Shang
Jinsai Shang
The RNA-dependent RNA polymerase (RdRp), 3C-like protease (3CL pro ), and papain-like protease (PL pro ) are pivotal components in the viral life cycle of SARS-CoV-2, presenting as promising therapeutic targets. Currently, all FDA-approved antiviral drugs against SARS-CoV-2 are RdRp or 3CL pro inhibitors. However, the mutations causing drug resistance have been observed in RdRp and 3CL pro from SARS-CoV-2, which makes it necessary to develop antivirals with novel mechanisms. Through the application of a structure-based drug design (SBDD) approach, we discovered a series of novel potent non-covalent PL pro inhibitors with remarkable in vitro potency and in vivo PK properties. The co-crystal structures of PL pro with leads revealed that the residues D164 and Q269 around the S2 site are critical for improving the inhibitor’s potency. The lead compound GZNL-P36 not only inhibited SARS-CoV-2 and its variants at the cellular level with EC50 ranging from 58.2 nM to 306.2 nM, but also inhibited HCoV-NL63 and HCoV-229E with EC50 of 81.6 nM and 2.66 μM, respectively. Oral administration of the compound resulted in significantly improved survival and notable reductions in lung viral loads and lesions in SARS- CoV-2 infection mouse model, consistent with RNA-seq data analysis. Our results indicate that PL pro inhibitor is a promising SARS-CoV-2 therapy.

21 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
YLYongzhi Lu
Yongzhi Lu
QYQi Yang
Qi Yang
RTRan Ting
Ran Ting
GZGuihua Zhang
Guihua Zhang
WLWenqi Li
Wenqi Li
JSJinsai Shang
Jinsai Shang